Trials / Recruiting
RecruitingNCT07131254
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT719 Injection | GT719 Injection |
Timeline
- Start date
- 2025-03-10
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2025-08-20
- Last updated
- 2025-12-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07131254. Inclusion in this directory is not an endorsement.